Sara Bastian

1.3k total citations
18 papers, 163 citations indexed

About

Sara Bastian is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Biomaterials. According to data from OpenAlex, Sara Bastian has authored 18 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Biomaterials. Recurrent topics in Sara Bastian's work include Colorectal Cancer Treatments and Studies (7 papers), Nanoparticle-Based Drug Delivery (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Sara Bastian is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Nanoparticle-Based Drug Delivery (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Sara Bastian collaborates with scholars based in Switzerland, Germany and United States. Sara Bastian's co-authors include Roger von Moos, Susan M. Domchek, Benoît You, Marianne Geiser, Helen K. Angell, Markus Joerger, Christoph Driessen, Ulrich Güller, Susana Banerjee and Richard T. Penson and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Sara Bastian

16 papers receiving 161 citations

Peers

Countries citing papers authored by Sara Bastian

Since Specialization

Citations

This map shows the geographic impact of Sara Bastian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Bastian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Bastian more than expected).

Fields of papers citing papers by Sara Bastian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Bastian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Bastian. The network helps show where Sara Bastian may publish in the future.

Co-authorship network of co-authors of Sara Bastian

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Bastian. A scholar is included among the top collaborators of Sara Bastian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Bastian. Sara Bastian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	35P TLD-1 – A novel liposomal doxorubicin formulation, in patients with advanced solid tumors: Final results of a multicenter, open-label, cross-over phase I study (SAKK 65/16) 2025 ·ESMO Open ·(unknown), Martina Klose, (unknown), (unknown), (unknown), Simon Haefliger, Manuela Rabaglio, Sara Bastian, (unknown), (unknown), Stefanie Hayoz, (unknown), (unknown), Robin Michelet, (unknown), (unknown), Charlotte Kloft, (unknown)	1
2	TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16) 2024 ·European Journal of Cancer ·Ilaria Colombo, (unknown), (unknown), Simon Haefliger, Manuela Rabaglio, Sara Bastian, (unknown), Katrin Eckhardt, Stefanie Hayoz, (unknown), Charlotte Kloft, (unknown), (unknown), Christian Baumgärtner, Cristiana Sessa, Anastasios Stathis, Dagmar Hess, Markus Joerger	10
3	First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17 2024 ·European Journal of Cancer ·Michael Mark, Patrizia Froesch, (unknown), Sacha I. Rothschild, Alfredo Addeo, Christoph Ackermann, (unknown), Martina Schneider, Karin Ribi, (unknown), Sara Bastian, Roger von Moos, Markus Joerger, Martin Früh	3
4	Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial 2024 ·Cancer Chemotherapy and Pharmacology ·(unknown), Dagmar Hess, Robin Michelet, Ilaria Colombo, Simon Haefliger, Sara Bastian, Manuela Rabaglio, (unknown), Stefanie Fischer, Katrin Eckhardt, Stefanie Hayoz, Christoph Kopp, (unknown), Cristiana Sessa, Anastasios Stathis, (unknown), Wilhelm Huisinga, Markus Joerger, Charlotte Kloft	5
5	Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD) 2024 ·International Journal of Molecular Sciences ·(unknown), Angélique Sadlon, Ursula Amstutz, (unknown), Martin D. Berger, Sara Bastian, Steven M. Offer, Carlo R. Largiadèr	1
6	First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. 2023 ·Journal of Clinical Oncology ·Michael Mark, Patrizia Froesch, (unknown), Sacha I. Rothschild, Alfredo Addeo, Christoph Ackermann, (unknown), Martina Schneider, Karin Ribi, (unknown), Sara Bastian, (unknown), Markus Joerger, Martin Früh	0
7	Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP) 2022 ·British Journal of Clinical Pharmacology ·(unknown), Cédric Bovet, Regula Theurillat, Laurent A. Décosterd, Carlo R. Largiadèr, Jean‐Christophe Prost, Chantal Csajka, Daniela Bärtschi, Matthias Gückenberger, Roger von Moos, Sara Bastian, Markus Joerger, Ulrich Jaehde	1
8	431P Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP) SAKK 41/16 2022 ·Annals of Oncology ·Sara Bastian, Markus Joerger, (unknown), (unknown), Matthias Gückenberger, (unknown), Dieter Koeberle, Alexander Siebenhüner, Martin D. Berger, (unknown), Carlo R. Largiadèr, (unknown), (unknown), Andreas Wicki, (unknown), (unknown)	0
9	Retrospective Analysis of Treatment Pathways in Patients With BRAF^V600E-mutant Metastatic Colorectal Carcinoma – MORSE^CRC 2022 ·Anticancer Research ·Armin Gerger, Wolfgang Eisterer, (unknown), Sara Bastian, Dieter Koeberle, Manfred Welslau, Dilara Akhoundova, (unknown), (unknown), (unknown), Richard Greil, (unknown), (unknown), (unknown), (unknown), (unknown), Dominik Paul Modest, Ralph Fritsch	3
10	TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). 2022 ·Journal of Clinical Oncology ·Dagmar Hess, Ilaria Colombo, Simon Haefliger, Manuela Rabaglio, Sara Bastian, (unknown), Katrin Eckhardt, (unknown), Stefanie Hayoz, Christoph Kopp, (unknown), (unknown), Charlotte Kloft, Cristiana Sessa, Anastasios Stathis, (unknown), Christian Baumgärtner, Markus Joerger	1
11	575P TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16) 2020 ·Annals of Oncology ·Dagmar Hess, Ilaria Colombo, Simon Haefliger, Sara Bastian, Manuela Rabaglio, Yannis Metaxas, Klaus Eckhardt, Christoph Kopp, Stefanie Hayoz, (unknown), Charlotte Kloft, Cristiana Sessa, Anastasios Stathis, Markus Joerger	2
12	814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC) 2020 ·Annals of Oncology ·Yvette Drew, Richard T. Penson, David M. O’Malley, JW Kim, Stefan Zimmermann, Patricia Roxburgh, Joohyuk Sohn, Salomon M. Stemmer, Sara Bastian, Michelle Ferguson, Benoît You, Susan M. Domchek, Haiyan Gao, Helen K. Angell, Kassondra Meyer, (unknown), Lone H. Ottesen, Daniel O. Koralek, Susana Banerjee	47
13	Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma 2019 ·Journal of Gastrointestinal Oncology ·Markus Joerger, Ulrich Güller, Sara Bastian, Christoph Driessen, Roger von Moos	16
14	Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) 2019 ·Annals of Oncology ·Susan M. Domchek, (unknown), S.-A. Im, Y.H. Park, J.P. Delord, Antoîne Italiano, Jérôme Alexandre, Benoît You, Sara Bastian, Matthew Krebs, Dee Dee Wang, (unknown), Mark C. Lanasa, Helen K. Angell, Zhongwu Lai, Christopher Gresty, (unknown), Pia Herbolsheimer, Bella Kaufman	41
15	Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10 2018 ·Journal of Geriatric Oncology ·Dirk Kienle, Daniel Dietrich, Karin Ribi, Andreas Wicki, Luca Quagliata, (unknown), Dieter Koeberle, Daniel Horber, Sara Bastian, (unknown), Piercarlo Saletti, Daniel Helbling, (unknown), Alessandro Lugli, J. Bernhard, (unknown), Roger von Moos	17
16	1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10 2015 ·European Journal of Cancer ·Dirk Kienle, Sun Young Rha, Dieter Koeberle, Daniel Horber, (unknown), Piercarlo Saletti, Daniel Helbling, Sara Bastian, Damien Dietrich, (unknown), (unknown), Roger von Moos	2
17	Surgical Resection of Isolated Adrenal Metastases in Patients with Non-Small Cell Lung Cancer: A Single-Institution Experience and Review of the Literature 2011 ·Onkologie ·Sara Bastian, Thomas Clerici, Jörg Neuweiler, Thomas Cerny, Martin Früh	4
18	Surface-lining layer of airways in cystic fibrosis mice 2003 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Marianne Geiser, Sara Bastian	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact